EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-in tergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group
10 –20% of patients with gastric cancer (GC) have HER2+ tumors. Addition of trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, HER2+ GC. When pertuzumab (P) w...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Anna Dorothea Wagner, Heike I. Grabsch, Murielle Mauer, Sandrine Marreaud, Carmela Caballero, Peter Thuss-Patience, Lothar Mueller, Annelie Elme, Markus Hermann Moehler, Uwe Martens, Yoon-Koo Kang, Sun Young Rha, Annemieke Cats, Masanori Tokunaga and Flor Tags: Study protocol Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin | Netherlands Health | Study